Fernando J. Muzzio - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Fernando J. Muzzio


Fernando J. Muzzio, PhD, is a Pharmtech editorial advisory board (EAB) member

Fernando J. Muzzio, PhD
Director, NSF Engineering Research Center on Structured Organic Particulate Systems, Department of
Chemical and Biochemical
Engineering,
Rutgers University

Fernando J. Muzzio is a professor in the Department of Chemical and Biochemical Engineering at Rutgers University. He currently serves as the director of the NSF Engineering Research Center on Structured Organic Particulate Systems, the director of the NSF-NIH Nanopharmaceutical Engineering IGERT training program, the co-chair of the technology subcommittee for the National Institute for Pharmaceutical Technology and Education. He is a member of the editorial boards of Pharmaceutical Technology and the Journal for Pharmaceutical Innovation.

Muzzio has published more than 140 peer-reviewed papers, written eight book chapters, presented numerous papers at major technical meetings, and holds six patents. He has been invited to present at numerous academic, industry, and federal seminars.

He received his PhD from the University of Massachusetts at Amherst in chemical engineering in 1991. His thesis was titled: "Non-Linearity, Chaos, and Self-Similarity: Effects of Mixing, Aggregation, Reaction, and Breakup on Structure Formation." He holds a BS in chemical engineering from the University of Mar del Plata, Argentina. 

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
26%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
43%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here